Abstract
To investigate the effects of intravesical application of oxybutynin chloride on bladder permeability we designed an animal model. Female Guinea pigs were given 3 different test solutions; phosphate buffered saline (PBS), 50% acetone and 1.27 × 10−2 M oxybutynin chloride solution. Then 99mTc-DTPA 45 μCi in 2 ml normal saline was instilled into the bladder lumen in each animals and allowed to dwell for 30 minutes. At the end of exposure time, the net count data in each 1 ml serum sample were corrected for radioactive decay and converted to the total percentage of administered dose. 99mTc-DTPA absorption percentages of both acetone and oxybutynin groups were significantly higher than that of PBS group (mean 3.2 ± 2.9% p < 0.001). Intravesical oxybutynin application increases bladder permeability 5 times compared with PBS administration. This observation can also explain how rapid absorption of oxybutynin through the bladder into the systemic circulation occurs.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kaplinsky R, Greenfield S, Wan J, Fera M. Expanded followup of intravesical oxybutynin chloride use in children with neurogenic bladder. J Urol 1996; 156: 753–756.
Greenfield SP, Fera M. The use of intravesical oxybutynin chloride in children in neurogenic bladder. J Urol 1991; 146: 532–534.
Mohler JL. Relaxation of intestinal bladders by intravesical oxybutynin chloride. Neurourol Urodynam 1990; 9: 179–181.
Madersbacher H, Jilg G. Control of detrusor hyperreflexia by the intravesical instillation of oxybutynin hydrochloride. Paraplegia 1991; 29: 84–87.
Massad CA, Kogan BA, Trigo-Rocha FE. The pharmacokinetics of intravesical and oral oxybutynin chloride. J Urol 1992: 148: 595–597.
Parsons CL et al. Bladder surface glycosaminoglycans: An epithelial permeability barrier. J Urol 1990; 143: 139–142.
Tzan CH, Berg J, Lewis SA. Effect of protamine sulfate on the permeability properties of the mammalian urinary bladder. J Membr Biol 1993; 133: 227–232.
Chelsky MJ et al. Bladder permeability in interstitial cystitis is similar to that of normal volunteers: Direct measurement by transvesical absorption of 99mTechnetiumdiethyl-enetriaminepentaacetic acid J Urol 1994; 151: 346–349.
Bonney WW, Robinson RA, Theobald RJ. Topical effect of intravesical oxybutynin. J Urol 1993; 150: 1522–1525.
Landau EH et al. Histologic studies of intravesical oxybutynin in the rabbit. J Urol 1995; 153: 2022–2024.
Amark P, Bussman G, Eksborg S. Follow-up of long-time treatment with intravesical oxybutynin for neurogenic bladder in children. Eur Urol 1998; 34: 148–153.
Teruo M, Watanabe H, Kobayashi T. Absorption of anti-cancer drug through bladder epithelium. Urology 1986; 27: 148–151.
Parsons CL, Greenspan C, Mulholland S. The primary antibacterial defense mechanism. Invest Urol 1975; 13: 72–74.
Tzan CJ, Berg J, Lewis SA. Mammalian urinary bladder permeability is altered by cationic proteins: Modulation by divalent cations. Am J Physiol, 267: 1013–1026.
Stein PC et al. Bladder injury model induced in rats by exposure to protamine sulfate followed by bacterial endotoxin. J Urol 1996; 155: 1133–1026.
Nickel JC et al. Relative efficacy of various exogenous glycosaminoglycans in providing a bladder surface permeability barrier. J Urol 1998; 160: 612–614.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ersay, A., Demirtas, O.C. Intravesical oxybutynin affects bladder permeability. Int Urol Nephrol 32, 359–361 (2001). https://doi.org/10.1023/A:1017595401988
Issue Date:
DOI: https://doi.org/10.1023/A:1017595401988